Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types

Dorothy Hallberg & Robert B. Scharpf et al.

Abstract

Endometrioid and mucinous ovarian carcinomas represent nearly a fifth of ovarian cancers, but their molecular characteristics and pathologic origins are poorly understood. To identify the genomic and epigenomic alterations characteristic of these ovarian cancer subtypes and evaluate links to morphologically similar tumors from other sites, we performed a combination of sequence, copy number, mutation signature, and rearrangement analyses from tumor samples and matched normal tissues of 133 patients, as well as methylation analyses of these tumors and tissues of 150 patients from The Cancer Genome Atlas. Genomic analyses included samples from patients with ovarian endometrioid (n = 44), ovarian mucinous (n = 43), uterine endometrioid (n = 15), and gastrointestinal mucinous carcinomas (n = 31), including mucinous carcinomas of the stomach, colon, and pancreas. In addition to identifying genes previously known to be involved in these tumors, we identified alterations in RAD51C, NOTCH4, SMARCA1/4, and JAK1 in ovarian endometrioid, ESR1 in uterine endometrioid, and SMARCA4 in ovarian mucinous carcinomas. Whole-genome sequencing revealed rearrangements involving PTEN, NF1, and NF2 in ovarian endometrioid carcinomas and NF1 and MED1 in ovarian mucinous carcinomas. The number of alterations, affected genes, and genome-wide methylation profiles were not distinguishable between ovarian and uterine endometrioid carcinomas, supporting the hypothesis that these tumors share a tissue of origin. In contrast, mutation and methylation patterns in ovarian mucinous carcinomas were different from gastrointestinal mucinous carcinomas. These analyses provide insights into the genomic landscapes and origins of mucinous and endometrioid ovarian carcinomas, providing new avenues for early clinical intervention and management of patients with these cancers.

Significance:

Integrative multi-omic analyses support a common tissue of origin between ovarian endometrioid and uterine endometrioid carcinomas but not between ovarian mucinous and gastric or pancreatic mucinous carcinomas.

Funding
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancerDevelopment of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancerDNA evaluation of fragments for early interception (DELFI) of Lung cancerLarge-Scale Genetic Analyses of Human CancerPacific Ovarian Cancer Research ConsortiumProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerPredoctoral Training Program in Human GeneticsCareer Enhancement ProgramHonorable Tina Brozman Foundation (Tina's Wish) FundingProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerPredoctoral Training Program in Human GeneticsCareer Enhancement ProgramU.S. Department of Defense (DOD) Grant OCRP-OC-100517Regional Oncology Research Center (Risk Factors)Pacific Ovarian Cancer Research ConsortiumLarge-Scale Genetic Analyses of Human CancerStand Up To Cancer (SU2C) Grant SU2C-AACR-DT1415Regional Oncology Research Center (Risk Factors)Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) FundingCommonwealth Foundation for Cancer Research Foundation FundingDNA evaluation of fragments for early interception (DELFI) of Lung cancerGray Foundation FundingDr. Miriam and Sheldon G. Adelson Medical Research Foundation FundingHonorable Tina Brozman Foundation Funding

NCI NIH HHS

U01 CA200469

National Institutes of Health (NIH)

CA200469

NCI NIH HHS

U01 CA271896

National Institutes of Health (NIH)

CA121113

NCI NIH HHS

P50 CA083636

NCI NIH HHS

P50 CA228991

NIGMS NIH HHS

T32 GM148383

National Institutes of Health (NIH)

CA062924

National Institutes of Health (NIH)

CA228991

National Institute of General Medical Sciences (NIGMS)

T32GM148383

NCI NIH HHS

P50 CA062924

NCI NIH HHS

P30 CA006973

National Institutes of Health (NIH)

CA083636

NCI NIH HHS

R01 CA121113

National Institutes of Health (NIH)

CA006973

National Institutes of Health (NIH)

CA271896

National Institutes of Health

CA121113

National Institutes of Health

CA006973

National Institutes of Health

CA062924

National Institutes of Health

CA083636

National Institutes of Health

CA200469

National Institutes of Health

CA271896

National Institutes of Health

CA228991

National Institute of General Medical Sciences

T32GM148383